NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-319 from the NIH Guide for Grants and Contracts. The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.
Notice NOT-AG-19-035 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-032 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-034 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-080 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The RTCCs are expected to work collaboratively with the Central Coordinating Site (CCS) as part of a PKD Research Consortium and serve as a national resource for the larger research community. The RTCCs should develop and share research resources (e.g. reagents, tools etc.), services and expertise that would be difficult or impractical to support in individual labs. The FOA is open to new applications, not renewals. Previously funded PKD Centers may apply as new centers.
Funding Opportunity RFA-DK-19-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The CCS is expected to work collaboratively with four RTCCs as part of the PKD Research Consortium and serve as a national resource for the larger research community. The CCS will provide central administrative and communications support for the Consortium. All activities within the Consortium are expected to address the overall goal of improving our understanding of the pathogenesis, progression, prevention and clinical management of PKD through enhanced sharing of resources and establishment of a robust research community. This FOA is a companion announcement to RFA-DK-19-010:Polycystic Kidney Disease Research and Translation Core Centers (U54).
Notice NOT-OD-19-128 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-063 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-020 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-031 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-318 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.
Notice NOT-OD-19-125 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-052 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-051 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-031 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-126 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-050 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-053 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-064 from the NIH Guide for Grants and Contracts